Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

NCT02583048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

NIH

Sponsor class

Conditions

Tuberculosis
HIV Infections

Interventions

DRUG: Bedaquiline
DRUG: Delamanid
DRUG: Dolutegravir
DRUG: Multidrug Background Treatment (MBT) for TB

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)